Natera, Inc. - NTRA STOCK NEWS

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, will announce its first-quarter financial results on May 6, 2021, after market close. The company is set to host a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results along with its business activities and future outlook.

Investors can participate via live dial-in or access the webcast for details. Natera focuses on advancing genetic testing services in women's health, oncology, and organ health, leveraging its CAP-accredited laboratories in Texas and California.

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, announced that the Centers for Medicare & Medicaid Services (CMS) has established a pathway for future coverage of its Prospera donor-derived cell-free DNA test for assessing transplant rejection in various solid organs. This follows existing coverage for kidney transplants. Natera has conducted over 3 million cfDNA tests and emphasizes the test's non-invasive nature and high precision. The release highlights the growing acceptance of dd-cfDNA monitoring as essential for organ transplant patient care.

Natera, Inc. (NASDAQ: NTRA) has introduced the first wave of its Panorama AI innovations, enhancing its non-invasive prenatal testing (NIPT) capabilities. Key improvements include:

• Increased positive predictive value for 22q11.2 deletion syndrome to 53%, the highest in the industry.
• 50% reduction in the no-call rate for aneuploidies with maintained sensitivity.
• Lowered cost of goods sold (COGS) due to workflow optimizations.

The changes aim to strengthen Natera's position in the NIPT market and are expected to contribute to profitability in 2021.

Natera, Inc. (NASDAQ: NTRA) has partnered with Tesis Labs to enhance prenatal genetic testing services across the U.S., including Texas, Colorado, and Arizona. This collaboration aims to improve access to genetic testing for over 4 million pregnancies annually, leveraging Tesis’s advanced laboratory capabilities in Lafayette, Colorado. Both companies emphasize the importance of early screening for informed healthcare decisions, thereby broadening Tesis's testing offerings and strategically positioning Natera in a growing market.

Natera, Inc. (NASDAQ: NTRA) has received two new Breakthrough Device Designations from the FDA for its Signatera molecular residual disease (MRD) test. These designations facilitate the development of Signatera as a companion diagnostic for two cancer therapies, adding to the existing 2019 designation. Over $65 million in contracts have been signed in the past year for Phase III clinical trials involving Signatera. This reflects Natera's commitment to advancing precision oncology and improving cancer treatment outcomes.

Natera, Inc. (NASDAQ: NTRA) announced the initiation of a phase III clinical trial using its Signatera test as a companion diagnostic for muscle-invasive urothelial carcinoma (MIUC) patients. This study, sponsored by Genentech, aims to evaluate the efficacy of atezolizumab in MRD-positive patients post-surgery. The trial seeks to enroll approximately 500 MRD-positive patients, with disease-free survival as the primary endpoint. Previous studies indicated significant benefits for MRD-positive patients treated with atezolizumab, highlighting the potential of Signatera in addressing unmet needs in bladder cancer treatment.

Natera, Inc. (NASDAQ: NTRA) reported strong financial results for Q4 2020, with total revenues of $112.4 million, a 35.1% increase from Q4 2019. Product revenues surged 43%, and tests processed reached approximately 295,000. For the full year, revenues climbed 29.3% to $391 million, surpassing guidance. The company announced successful clinical trial results and expanded its oncology portfolio. Despite operating expenses rising to $126.5 million, resulting in a net loss of $76.4 million for Q4 2020, the outlook for 2021 is optimistic with expected revenues between $500 million and $525 million.

Natera, a leader in cell-free DNA testing, will present at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 11:10 a.m. PT (2:10 p.m. ET). CFO Mike Brophy will discuss recent company activities and engage in a Q&A session. The live webcast and archived presentation will be accessible via investor.natera.com. Natera aims to revolutionize disease management with a focus on women's health, oncology, and organ health, operating ISO-certified labs in California and Texas.

Natera, a leader in cell-free DNA testing, will announce its fourth quarter and year-end financial results on February 25, 2021, after market close. A conference call will follow at 1:30 p.m. PT to discuss the results, business activities, and outlook. Investors can join via live dial-in or through a webcast available on their website. Natera aims to revolutionize disease management with its innovative testing solutions, focusing on women's health, oncology, and organ health.